Literature DB >> 7145465

A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse.

A A McColm, R Bomford, L Dalton.   

Abstract

The protective immunity conferred by subcutaneous injection of outbred CD-1 mice with a killed Plasmodium yoelii (YM strain) vaccine was strongly potentiated by saponin. By adjusting the dose of antigen, the number of immunizations and the number of living parasites in the challenge infection, conditions were defined where antigen alone was non-protective but 100% protection was obtained by the addition of saponin. Inbred BALB/c, CBA/CA and C57 B1 mice were much less responsive than the CD-1 mice. The following adjuvants were compared with saponin: mineral oil emulsions (Freund's incomplete and complete adjuvants); A1(OH)3(Alhydrogel); bacteria and synthetic bacterial derivatives (Bordetella pertussis, Corynebacterium parvum and muramyl dipeptide); surface active materials (digitonin, vitamin A, Arquad 18, dimethyldioctadecyl ammonium bromide, and the polyene antibiotics, Nystatin and Amphotericin B). None of these adjuvants were as effective as saponin, although FCA, A1(OH)3 and C. parvum augmented immunity considerably. The possible reasons for the efficacy of saponin as an adjuvant for protozoal vaccines are discussed. The P. yoelli/mouse system provides a sensitive and rapid screening assay for comparison of potential adjuvants suitable for use with a malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7145465     DOI: 10.1111/j.1365-3024.1982.tb00445.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  9 in total

1.  Towards a Taenia solium cysticercosis vaccine: an epitope shared by Taenia crassiceps and Taenia solium protects mice against experimental cysticercosis.

Authors:  A Toledo; C Larralde; G Fragoso; G Gevorkian; K Manoutcharian; M Hernández; G Acero; G Rosas; F López-Casillas; C K Garfias; R Vázquez; I Terrazas; E Sciutto
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  The dichotomy (generation of MAbs with functional heterogeneity) in antimalarial immune response in vaccinated/protected mice: a new concept in our understanding of the protective immune mechanisms in malaria.

Authors:  Prati Pal Singh; Bhanu Prakash
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

3.  Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens.

Authors:  J M Burns; P D Dunn; D M Russo
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Efficacy of purified Anaplasma marginale initial bodies as a vaccine against anaplasmosis.

Authors:  S Montenegro-James; M A James; M T Benitez; E Leon; B K Baek; A T Guillen
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

5.  Saponin adjuvant primes for a dominant interleukin-10 production to ovalbumin and to Trypanosoma cruzi antigen.

Authors:  C E Tadokoro; M S Macedo; I A Abrahamsohn
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

8.  Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies.

Authors:  S R Chavali; L D Barton; J B Campbell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

9.  Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes.

Authors:  J M Burns; E K Adeeku; P D Dunn
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.